Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
15 mai 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides...
Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference
04 mai 2023 16h05 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 04, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented...
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
24 avr. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 24, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the appointment of Fred Hassan to its Board of Directors, increasing its...
Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference
18 avr. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 18, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the acceptance of an oral presentation containing new data from the...
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
10 avr. 2023 08h30 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common...
Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
29 mars 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral...
Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023
22 mars 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit...
Cocrystal Pharma Announces Participation in Virtual Investor Events
26 janv. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation of James Martin, co-CEO and CFO, in the following virtual investment community...
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
19 déc. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results for its orally administered replication inhibitor...
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
01 déc. 2022 16h05 HE
|
Cocrystal Pharma, Inc.
Affirms plans to report topline Phase 1 results in 2022 and to initiate Phase 2a influenza human challenge trial in 2023 BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc....